nach oben

Erschienen in:

24.03.2017 | Phototherapie | Fortbildung

Geringe Nebenwirkungen, hoher logistischer Aufwand

Phototherapie sklerosierender Hautkrankheiten

verfasst von: Matthias Hahn, PD Dr. med. Kamran Ghoreschi

Erschienen in: hautnah dermatologie | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Verschiedene sklerosierende Hautkrankheiten sind einer Phototherapie zugänglich. Bei der Plaque-Morphea und beim Lichen sclerosus kann die Phototherapie nicht nur den Progress der Krankheit aufhalten, sondern sogar zu einer vollständigen Abheilung der Läsionen führen. Bei der systemischen Sklerodermie ist das Therapieziel dagegen zumeist das Fortschreiten der Erkrankung zu verlangsamen und die Sklerose der Haut zu verbessern.

Kerscher, M., et al. Treatment of localised scleroderma with PUVA bath photochemotherapy. Lancet 1994; 343: 1233CrossRefPubMed

Kerscher, M., Dirschka, T., and Volkenandt, M. Treatment of localised scleroderma by UVA1 phototherapy. Lancet 1995; 346: 1166CrossRefPubMed

Kreuter, A., et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006; 54: 440–7CrossRefPubMed

Herzinger, T., et al. S1-Leitlinie zur UV-Phototherapie und Photochemotherapie. J Dtsch Dermatol Ges 2016; 14: e1–e25CrossRefPubMed

York, N.R. and Jacobe, H.T. UVA1 phototherapy: a review of mechanism and therapeutic application. Int J Dermatol 2010; 49: 623–30CrossRefPubMed

Godar, D.E. UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol 1999; 112: 3–12CrossRefPubMed

Guhl, S., et al. Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells. J Invest Dermatol 2003; 121: 837–44CrossRefPubMed

Grabbe, J., et al. High-dose ultraviolet A1 (UVA1), but not UVA/UVB therapy, decreases IgE-binding cells in lesional skin of patients with atopic eczema. J Invest Dermatol 1996; 107: 419–22CrossRefPubMed

Kreuter, A., et al. Ultraviolet A1-induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol 2006; 155: 600–7CrossRefPubMed

10.

El-Mofty, M., et al. Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study. Photodermatol Photoimmunol Photomed 2004; 20: 93–100CrossRefPubMed

11.

Edwards, D.R., et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987; 6: 1899–904PubMedPubMedCentral

12.

Kawaguchi, Y., Hara, M., and Wright, T.M. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103: 1253–60CrossRefPubMedPubMedCentral

13.

Duncan, M.R. and Berman, B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991; 97: 686–92CrossRefPubMed

14.

Bernerd, F. and Asselineau, D. UVA exposure of human skin reconstructed in vitro induces apoptosis of dermal fibroblasts: subsequent connective tissue repair and implications in photoaging. Cell Death Differ 1998; 5: 792–802CrossRefPubMed

15.

Scharffetter, K., et al. UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 1991; 283: 506–11CrossRefPubMed

16.

Gruss, C., et al. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 1997; 350: 1295–6CrossRefPubMed

17.

Herrmann, G., et al. UVA irradiation stimulates the synthesis of various matrix-metalloproteinases (MMPs) in cultured human fibroblasts. Exp Dermatol 1993; 2: 92–7CrossRefPubMed

18.

Kiss, M., et al. Alpha-melanocyte stimulating hormone induces collagenase/matrix metalloproteinase-1 in human dermal fibroblasts. Biol Chem Hoppe Seyler 1995; 376: 425–30CrossRefPubMed

19.

Brenneisen, P., et al. Hydrogen peroxide (H₂O₂) increases the steady-state mRNA levels of collagenase/MMP-1 in human dermal fibroblasts. Free Radic Biol Med 1997; 22: 515–24CrossRefPubMed

20.

Sakura, S., et al. Photolysis of pyridinoline, a cross-linking amino acid of collagen, by ultraviolet light. Can J Biochem 1982; 60: 525–9CrossRefPubMed

21.

Johnston, K.J., et al. Ultraviolet radiation-induced connective tissue changes in the skin of hairless mice. J Invest Dermatol 1984; 82: 587–90CrossRefPubMed

22.

Oikarinen, A., et al. Connective tissue alterations in skin exposed to natural and therapeutic UV-radiation. Photodermatol 1985; 2: 15–26PubMed

23.

Klimas, N.K., et al. Health-related quality of life in morphoea. Br J Dermatol 2015; 172: 1329–37CrossRefPubMedPubMedCentral

24.

Kroft, E.B., et al. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol 2008; 59: 1017–30CrossRefPubMed

25.

Durand, F., et al. Ultraviolet A1 phototherapy for treatment of acrosclerosis in systemic sclerosis: controlled study with half-side comparison analysis. Photodermatol Photoimmunol Photomed 2007; 23: 215–21CrossRefPubMed

26.

Luftl, M., et al. Psoralen bath plus UV-A therapy. Possibilities and limitations. Arch Dermatol 1997; 133: 1597–603

27.

Usmani, N., et al. Photochemotherapy for systemic sclerosis: effect on clinical and molecular markers. Clin Exp Dermatol 2010; 35: 608–13CrossRefPubMed

28.

Kanekura, T., et al. Successful treatment of scleroderma with PUVA therapy. J Dermatol 1996; 23: 455–9CrossRefPubMed

29.

Hofer, A. and Soyer, H.P. Oral psoralen-UV-A for systemic scleroderma. Arch Dermatol 1999; 135: 603–4CrossRefPubMed

30.

von Kobyletzki, G., et al. Acrosclerosis in patients with systemic sclerosis responds to low-dose UV-A1 phototherapy. Arch Dermatol 2000; 136: 275–6CrossRef

31.

Morita, A., et al. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43: 670–4CrossRefPubMed

32.

Kreuter, A., et al. Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol 2004; 50: 740–7CrossRefPubMed

33.

Pereira, N., et al. Low-dose UVA(1) phototherapy for scleroderma: what benefit can we expect? J Eur Acad Dermatol Venereol 2012; 26: 619–26CrossRefPubMed

34.

Rose, R.F., et al. Low-dose UVA1 phototherapy for proximal and acral scleroderma in systemic sclerosis. Photodermatol Photoimmunol Photomed 2009; 25: 153–5CrossRefPubMed

35.

Jacobe, H.T., Cayce, R., and Nguyen, J. UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V. Br J Dermatol 2008; 159: 691–6CrossRefPubMed

36.

Fett, N. and Werth, V.P. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 2011; 64: 217–28; quiz 229-30CrossRefPubMed

37.

Röcken, M. and Ghoreschi, K. In: Bolognia J. et al (Hg). Dermatology. - 3rd ed. Elsevier 2012; 657–86

38.

Gruss, C., et al. Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood. Br J Dermatol 1997; 136: 293–4CrossRefPubMed

39.

Kreuter, A., et al. German guidelines for the diagnosis and therapy of localized scleroderma. J Dtsch Dermatol Ges 2016; 14: 199–216CrossRefPubMed

40.

Pavlotsky, F., et al. Bath psoralen-UVA photochemotherapy for localized scleroderma: experience from a single institute. Photodermatol Photoimmunol Photomed 2013; 29: 247–52CrossRefPubMed

41.

tege, H., et al. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol 1997; 36: 938–44CrossRef

42.

Gruss, C.J., et al. Effects of low dose ultraviolet A-1 phototherapy on morphea. Photodermatol Photoimmunol Photomed 2001; 17: 149–55CrossRefPubMed

43.

Camacho, N.R., et al. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol 2001; 45: 697–9CrossRefPubMed

44.

de Rie, M.A., et al. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. Dermatology 2003; 207: 298–301CrossRefPubMed

45.

Rombold, S., et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008; 24: 19–23CrossRefPubMed

46.

Sator, P.G., et al. Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment. J Am Acad Dermatol 2009; 60: 786–91CrossRefPubMed

47.

Su, O., et al. Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma. Int J Dermatol 2011; 50: 1006–13CrossRefPubMed

48.

Andres, C., et al. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br J Dermatol 2010; 162: 445–7CrossRefPubMed

49.

Kreuter, A., et al. Low-dose ultraviolet-A1 phototherapy for lichen sclerosus et atrophicus. Clin Exp Dermatol 2001; 26: 30–2CrossRefPubMed

50.

Kreuter, A., et al. Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study. J Am Acad Dermatol 2002; 46: 251–5CrossRefPubMed

51.

von Kobyletzki, G., et al. [Balneophotochemotherapy with 8-methoxypsoralen in lichen sclerosis et atrophicus]. Hautarzt 1997; 48: 488–91CrossRef

52.

Reichrath, J., Reinhold, U., and Tilgen, W. Treatment of genito-anal lesions in inflammatory skin diseases with PUVA cream photochemotherapy: an open pilot study in 12 patients. Dermatology 2002; 205: 245–8CrossRefPubMed

53.

Dalmau, J., et al. Psoralen-UVA treatment for generalized prepubertal extragenital lichen sclerosus et atrophicus. J Am Acad Dermatol 2006; 55: S56–8CrossRefPubMed

54.

Ghoreschi, K. and Rocken, M. Phototherapy of sclerosing skin diseases. Dermatology 2002; 205: 219–20CrossRefPubMed

55.

Kirtschig, G., et al. Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus. J Eur Acad Dermatol Venereol 2015; 29: e1–43CrossRefPubMed

56.

Grundmann-Kollmann, M., et al. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000; 42: 134–6CrossRefPubMed

57.

Stander, H., Schiller, M., and Schwarz, T. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol 2002; 46: 799–800CrossRefPubMed

58.

Calzavara Pinton, P., et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica 2003; 88: 1169–75PubMed

59.

Wetzig, T., et al. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005; 35: 515–9CrossRefPubMed

60.

Ghoreschi, K., et al. PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease. Eur J Dermatol 2008; 18: 667–70PubMed

61.

Weber, H.O., et al. Eosinophilic fasciitis and combined UVA1—retinoid—corticosteroid treatment: two case reports. Acta Derm Venereol 2008; 88: 304–6PubMed

62.

Schiener, R., et al. Eosinophilic fasciitis treated with psoralen-ultraviolet A bath photochemotherapy. Br J Dermatol 2000; 142: 804–7CrossRefPubMed

63.

Connolly, K.L., et al. Ultraviolet A1 phototherapy beyond morphea: experience in 83 patients. Photodermatol Photoimmunol Photomed 2015; 31: 289–95CrossRefPubMed

64.

Kafi, R., et al. UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 2004; 140: 1322–4CrossRefPubMed

65.

Tran, K.T., et al. UV-A1 therapy for nephrogenic systemic fibrosis. Arch Dermatol 2009; 145: 1170–4CrossRefPubMed

66.

Eberlein-Konig, B., et al. Successful UVA1 phototherapy in a patient with scleredema adultorum. J Eur Acad Dermatol Venereol 2005; 19: 203–4CrossRefPubMed

67.

Gambichler, T. et al. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies. Clin Dermatol 2013; 31: 438–54CrossRefPubMed

Titel: Geringe Nebenwirkungen, hoher logistischer Aufwand
Phototherapie sklerosierender Hautkrankheiten
verfasst von: Matthias Hahn
PD Dr. med. Kamran Ghoreschi
Publikationsdatum: 24.03.2017
Verlag: Springer Medizin
Schlagwörter: Phototherapie
Systemische Sklerodermie
Lichen sclerosus
Eosinophile Fasziitis
Erschienen in: hautnah dermatologie / Ausgabe 2/2017
Print ISSN: 0938-0221
Elektronische ISSN: 2196-6451
DOI: https://doi.org/10.1007/s15012-017-2380-3

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

16.04.2024 | Infektiologie | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Phototherapie sklerosierender Hautkrankheiten

Zusammenfassung

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Hypertrophe Narben bessern sich mit Narben-Gel

Neuer Lichtblick in der topischen Aknetherapie

Neuer Ansatz gegen Akne

Allergologischer Rundumschlag

Vorsicht bei der Selbstbehandlung von Schwielen und Clavi!

Ein 30 Jahre alter Begleiter an der Brust

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Dupilumab ist mit kutanen T-Zell-Lymphomen assoziiert

Chemotherapie mit Hindernissen

Update Dermatologie